BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia

Azacitidine (AZA), the reference treatment for most higher-risk myelodysplastic (MDS) patients can also improve overall survival (OS) in elderly acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy, but reliable biological markers predicting response and OS in patients treated...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Vidal, Valérie, Robert, Guillaume, Goursaud, Laure, Durand, Laetitia, Ginet, Clemence, Karsenti, Jean Michel, Luciano, Frederic, Gastaud, Lauris, Garnier, Georges, Braun, Thorsten, Hirsch, Pierre, Raffoux, Emmanuel, Nloga, Anne Marie, Padua, Rose Ann, Dombret, Hervé, Rohrlich, Pierre, Ades, Lionel, Chomienne, Christine, Auberger, Patrick, Fenaux, Pierre, Cluzeau, Thomas
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2017
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564547/
https://ncbi.nlm.nih.gov/pubmed/28514758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17482
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items